Touting a wad of cash in the wake of a clinical implosion, a small biotech reviews some limited options

Just two short months after TYME Technologies’ lead drug candidate SM-88 was pulled from a failed Phase II/III trial for metastatic pancreatic cancer, the microcap biotech is now looking at restructuring in what seems to be a last-ditch attempt to stay afloat.